anti human caix mab  (Revvity Signals)

Journal: International Journal of Nanomedicine

Article Title: CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

doi: 10.2147/IJN.S176287

Figure Lengend Snippet: Loading ability of targeted nanobubbles. Notes: ( A ) Red fluorescence of DiI-labeled lipid membranes. ( B ) Green fluorescence of 6-FAM modified CAIX aptamer. ( C ) The merged image confirms targeted nanobubbles were loaded with CAIX aptamer. Abbreviations: DiI, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate; 6-FAM, 6-carboxyfluorescein; CAIX, carbonic anhydrase IX.

Article Snippet: The membrane was blocked with 5% non-fat milk, incubated with rabbit anti-human CAIX monoclonal antibody (1:1,000; Abcam) at 4°C overnight and horseradish peroxidase-labeled goat anti-rabbit antibody (1:1,000; Beyotime Institute of Biotechnology) for 1 hour.

Techniques: Fluorescence, Labeling, Modification

Journal: International Journal of Nanomedicine

Article Title: CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

doi: 10.2147/IJN.S176287

Figure Lengend Snippet: Ability of targeted nanobubbles to load CAIX aptamer in xenograft tumor tissues. Notes: The ability of targeted nanobubbles to load CAIX aptamer in 786-O xenograft tumor tissues (upper), in Hela xenograft tumor tissues (middle), and in BxPC-3 xenograft tumor tissues (lower). Blue fluorescence indicates cell nuclei, red fluorescence indicates the lipid membranes of targeted nanobubbles, and green fluorescence indicates CAIX aptamer. Abbreviations: TN, targeted nanobubbles; CAIX, carbonic anhydrase IX.

Article Snippet: The membrane was blocked with 5% non-fat milk, incubated with rabbit anti-human CAIX monoclonal antibody (1:1,000; Abcam) at 4°C overnight and horseradish peroxidase-labeled goat anti-rabbit antibody (1:1,000; Beyotime Institute of Biotechnology) for 1 hour.

Techniques: Fluorescence

Journal: International Journal of Molecular Sciences

Article Title: Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX

doi: 10.3390/ijms131013030

Figure Lengend Snippet: Fluorescence-activated cell sorting analysis. ( A ) Autofluorescence of HCT116 cells at 530nm (FL1). ( B ) Fluorescence of HCT116 cells after incubation with FITC-CaIX-P1. ( C ) Autofluorescence of HCT116 cells at 590nm (FL2). ( D ) Fluorescence of HCT116 cells after incubation with rhodamine-labeled anti-CAIX-mAb.

Article Snippet: Cells incubated with anti-human CAIX-mAb were further incubated with a rhodamine conjugated anti-mouse IgG (Rockland, 610-4002) or an Alexa fluor conjugated IgG overnight.

Techniques: Fluorescence, FACS, Incubation, Labeling

Journal: International Journal of Molecular Sciences

Article Title: Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX

doi: 10.3390/ijms131013030

Figure Lengend Snippet: Fluorescence-activated cell sorting analysis after co-icubation of HCT116 cells with FITC-labeled CaIX-P1 and rhodamine-labeled anti-human CAIX mAb. Low left box : unlabeled cells (autofluorescence). Low right box : cells labeled only with FITC-CaIX-P1. Upper left box : cells labeled only with rhodamine-anti-CAIX-mAb. Upper right box : Cells labeled with both FITC-CaIX-P1 and rhodamine-anti-CAIX-mAb.

Article Snippet: Cells incubated with anti-human CAIX-mAb were further incubated with a rhodamine conjugated anti-mouse IgG (Rockland, 610-4002) or an Alexa fluor conjugated IgG overnight.

Techniques: Fluorescence, FACS, Labeling

Journal: International Journal of Molecular Sciences

Article Title: Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX

doi: 10.3390/ijms131013030

Figure Lengend Snippet: Fluorescence-activated cell sorting analysis. ( A ) Autofluorescence of HT29 cells at 530nm (FL1). ( B ) Fluorescence of HT29 cells after incubation with FITC-CaIX-P1. ( C ) Autofluorescence of HT29 cells at 590nm (FL2). ( D ) Fluorescence of HT29 cells after incubation with rhodamine-labeled anti-CAIX-mAb.

Article Snippet: Cells incubated with anti-human CAIX-mAb were further incubated with a rhodamine conjugated anti-mouse IgG (Rockland, 610-4002) or an Alexa fluor conjugated IgG overnight.

Techniques: Fluorescence, FACS, Incubation, Labeling

Journal: International Journal of Molecular Sciences

Article Title: Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX

doi: 10.3390/ijms131013030

Figure Lengend Snippet: Fluorescence-activated cell sorting analysis. ( A ) Autofluorescence of BxPC3 cells at 530nm (FL1). ( B ) Fluorescence of BxPC3 cells after incubation with FITC-CaIX-P1. ( C ) Autofluorescence of BxPC3 cells at 488nm (FL3). ( D ) Fluorescence of BxPC3 cells after incubation with Alexa Fluor-labeled anti-CAIX-mAb.

Article Snippet: Cells incubated with anti-human CAIX-mAb were further incubated with a rhodamine conjugated anti-mouse IgG (Rockland, 610-4002) or an Alexa fluor conjugated IgG overnight.

Techniques: Fluorescence, FACS, Incubation, Labeling

Journal: Neoplasia (New York, N.Y.)

Article Title: Combination of sunitinib and 177 Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

doi: 10.1016/j.neo.2022.100826

Figure Lengend Snippet: Tumor growth of SK-RC-52 tumors and survival of mice during treatment with sunitinib (Su) and/or [ 177 Lu]Lu -cG250 radioimmunotherapy (RIT). ( A-F) Growth curves of individual mice. ( A) Su+[ 177 Lu]Lu -cG250 RIT one cycle, ( B) Su+[ 177 Lu]Lu -cG250 RIT two cycles, ( C) [ 177 Lu]Lu -cG250 RIT one cycle, ( D) [ 177 Lu]Lu -cG250 RIT two cycles, ( E) Su two cycles, ( F ) Control. ( G) Mean tumor volume of all treatment groups, * p < 0.05, *** p < 0.001. P-values shown are Holm's adjusted for the comparison of mean tumor volumes for comparisons of all treatment groups vs control group on day 98 (end of 2 nd cycle). ( H) overall survival of treatment groups. Mice that were sacrificed because of other reasons than reaching maximal tumor burden, were excluded. Overall comparison of survival curves was significant with p<0.05. P-values shown for the Su+[ 177 Lu]Lu -cG250 RIT one cycle, two cycles and [ 177 Lu]Lu -cG250 RIT two cycles all vs Control were calculated from the log rank or Gehan-Breslow-Wilcoxon test corrected for multiple comparisons (p=0.0124 for Su+[ 177 Lu]Lu -cG250 RIT two cycles vs Control, p= 0.0468 for Su+[ 177 Lu]Lu -cG250 RIT one cycle vs Control and p= 0.129 for [ 177 Lu]Lu -cG250 RIT two cycles vs Control).

Article Snippet: Primary antibodies used were chimeric mAb anti-human CAIX (mAb cG250, Wilex, 10 µg/mL), rabbit-anti-human mAb Ki67 (clone sp6/RM-9106-S, Thermo Fisher Scientific, 1:200), rabbit-anti-human mAb MET (D1C2, cell signaling #8198S, 1:200), polyclonal rabbit-anti-human AXL (Proteintech #13196-1-AP, 1:250).

Techniques:

Journal: Neoplasia (New York, N.Y.)

Article Title: Combination of sunitinib and 177 Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

doi: 10.1016/j.neo.2022.100826

Figure Lengend Snippet: Tumor growth and survival of NU12 tumors during treatment with sunitinib (Su) and/or [ 177 Lu]Lu -cG250 radioimmunotherapy (RIT). ( A-F) Growth curves of individual mice. ( A) Su+[ 177 Lu]Lu cG250 RIT one cycle, ( B) Su+[ 177 Lu]Lu -cG250 RIT two cycles, ( C) [ 177 Lu]Lu -cG250 RIT one cycle, ( D) [ 177 Lu]Lu -cG250 RIT two cycles, ( E) Su two cycles, ( F) Control. ( G,H) Mean tumor volume of all treatment groups. *** P< 0.001. P-values shown are Holm's adjusted for the comparison of mean tumor volumes for comparisons of all treatment groups vs control group on day 91 (end of 2 nd cycle) ( I) Overall survival of treatment groups. Mice that were sacrificed because of other reasons than reaching maximal tumor burden, were excluded. Overall comparison of survival curves was significant with p<0.0001. P-values shown for all treatment groups vs Control were calculated from the log rank or Gehan-Breslow-Wilcoxon test corrected for multiple comparisons (**** p<0.0001). 1x: one cycle. 2x: two cycles.

Article Snippet: Primary antibodies used were chimeric mAb anti-human CAIX (mAb cG250, Wilex, 10 µg/mL), rabbit-anti-human mAb Ki67 (clone sp6/RM-9106-S, Thermo Fisher Scientific, 1:200), rabbit-anti-human mAb MET (D1C2, cell signaling #8198S, 1:200), polyclonal rabbit-anti-human AXL (Proteintech #13196-1-AP, 1:250).

Techniques: